In addition to genetic events, a variety of epigenetic events have been widely reported to
contribute to the onset of many diseases including cancer. DNA methylation and histone …

Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs)
that become unresponsive to standard treatments, such as docetaxel and enzalutamide …

Histone deacetylases (HDACs) are frequently overexpressed in broad range of cancer
types, where they alter cellular epigenetic programming to promote cell proliferation and …

Intratumoral innate immunity can play a significant role in blocking the effective therapeutic
spread of a number of oncolytic viruses (OVs). Histone deacetylase inhibitors (HDIs) are …

Despite much progress in prostate cancer management, new diagnostic, prognostic and
therapeutic tools are needed to predict disease severity, choose among the available …

Epigenetic modifications play a key role in the patho-physiology of prostate cancer. Histone
deacetylases (HDACs) play major roles in prostate cancer progression. HDACs are part of a …

During cancer development and progression, tumor cells undergo abnormal epigenetic
modifications, including DNA methylation, histone deacetylation and nucleosome …

BACKGROUND: This phase 2 trial was designed to evaluate the efficacy of vorinostat in
chemotherapy‐pretreated patients with metastatic castration‐resistant prostate cancer …

BACKGROUND Metastatic prostate cancer is either inherently resistant to chemotherapy or
rapidly acquires this phenotype after chemotherapy exposure. In this study, we identified a …

Prostate cancer is one of the most common non-cutaneous malignancies among men
worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or …